Related Experiment Videos
Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis
M R Lilien1, M Duran, J M Quak
1Pediatric Renal Centre and Laboratory for Metabolic Diseases, Wilhelmina Children's Hospital, Utrecht, The Netherlands. m.lilien@wkz.azu.nl
Pediatric Nephrology (Berlin, Germany)
|November 30, 2000
Summary
L-carnitine supplementation did not reduce the need for recombinant human erythropoietin (rhEPO) in children with chronic kidney disease on dialysis. This study found no significant changes in rhEPO requirements or hemoglobin levels.
Area of Science:
- Pediatric Nephrology
- Hematology
- Nutritional Science
Background:
- Recombinant human erythropoietin (rhEPO) treats anemia in pediatric chronic renal failure but is costly.
- L-carnitine supplementation may reduce rhEPO needs in adults with anemia.
Purpose of the Study:
- To evaluate the impact of oral L-carnitine on rhEPO requirements in children undergoing dialysis.
- To assess changes in hematological parameters with L-carnitine supplementation.
Main Methods:
- A prospective study involving 16 children on hemodialysis or peritoneal dialysis.
- Children received L-carnitine (20 mg/kg/day) for 26 weeks, with baseline and follow-up data collection.
- Measured rhEPO requirements, hemoglobin, hematocrit, and carnitine levels.
Main Results:
- L-carnitine supplementation significantly increased free and total carnitine levels (P<0.05).
- No significant reduction in rhEPO requirement was observed.
- Hemoglobin and hematocrit levels remained unchanged throughout the study.
Conclusions:
- Oral L-carnitine supplementation did not demonstrate a beneficial effect on rhEPO requirement in pediatric dialysis patients.
- Further research may be needed to explore L-carnitine's role in pediatric anemia management in renal failure.